Kaplan-Meier curve showing the probability of relapse-free survival over time. A landmark was set at year 2 to group patients with or without the evolution of subclones containing CLL-relevant mutations up to that point. The red line includes any patient with baseline TP53 mutations, the green line includes patients without baseline TP53 mutations who had at least one evolving CLL-relevant mutation in the first 2 years of treatment, and the blue line includes patients without baseline TP53 mutations or evolving CLL-relevant mutations at year 2. The x-axis represents the relapse-free survival time since the second year of treatment. There is a significant difference in the relapse-free survival of patients who do not have CLL-relevant evolution in the first 2 years compared with those who do (log-rank P = .0004 when comparing the green and blue lines).